Green tea is NOT safe to take with Coversyl (perindopril) and metoprolol
Green tea significantly reduces the absorption and blood levels of both perindopril (an ACE inhibitor like Coversyl) and metoprolol (a beta-blocker), which can lead to inadequate blood pressure control and increased cardiovascular risk.
The Evidence for Drug Interactions
Direct Evidence with ACE Inhibitors
Green tea catechins, particularly (-)-epigallocatechin gallate (EGCG), dramatically impair the intestinal absorption of ACE inhibitors. In a controlled clinical study with lisinopril (another ACE inhibitor in the same class as perindopril), green tea extract reduced drug absorption by approximately 70% 1. The geometric mean ratio showed maximum plasma concentration decreased to 0.289 and area under the curve to 0.337 compared to control 1. This interaction occurs at the intestinal level by inhibiting OATP uptake transporters, particularly OATP1A2, which are responsible for drug absorption 2, 3.
Direct Evidence with Beta-Blockers
Green tea has been documented to reduce beta-blocker absorption by up to 98-99% 2. In a study with celiprolol (another beta-blocker), green tea decreased the area under the serum concentration-time curve and urinary excretion by 98.6% and 98.0%, respectively 4. While this specific study wasn't with metoprolol, the mechanism applies across beta-blockers that rely on intestinal absorption 5.
Clinical Implications
Risk of Treatment Failure
Both perindopril and metoprolol are prescribed for critical cardiovascular conditions including:
- Hypertension control 6, 7
- Post-myocardial infarction protection 8, 9
- Heart failure management 10
- Stable coronary artery disease 6
Reduced drug absorption means inadequate blood pressure control, increased risk of cardiovascular events, and potential treatment failure 1, 3. The EUROPA trial specifically demonstrated that perindopril reduces cardiovascular events in stable coronary disease 6, but this benefit requires adequate drug levels.
Mechanism of Interaction
The interaction occurs through multiple pathways 2, 3:
- Inhibition of OATP1A2 and OATP2B1 transporters in the intestine, blocking drug uptake
- Potential effects on P-glycoprotein efflux, further reducing absorption
- Reduced drug solubility in the gastrointestinal tract
These effects are dose-dependent and occur with typical green tea consumption (approximately 300 mg EGCG per serving) 1.
Important Caveats
Timing Considerations
The interaction studies used green tea consumed at the same time as medication 1, 4. Separating green tea consumption from medication timing by several hours might reduce but not eliminate the interaction, as the inhibitory effects on transporters can persist.
Individual Variability
Studies show high inter-individual variability in the magnitude of interaction 3, 5. Some patients may experience more severe reductions in drug absorption than others, making it impossible to predict who will be affected most.
Real-World Evidence
Case reports have associated green tea consumption with reduced efficacy of cardiovascular medications, including nadolol (a beta-blocker) 2. These real-world observations support the clinical significance of the pharmacokinetic data.
Clinical Recommendation
Patients taking Coversyl (perindopril) and metoprolol should avoid green tea consumption entirely, including:
- Brewed green tea beverages
- Green tea extracts or supplements
- Products containing green tea catechins
If blood pressure control becomes inadequate or cardiovascular symptoms worsen in a patient who consumes green tea, consider this interaction as a potential cause of treatment failure 1, 3. The combination of perindopril and metoprolol is evidence-based and effective for hypertension management 11, but only when adequate drug levels are achieved.
Alternative Beverages
While the evidence provided mentions other teas (chamomile, peppermint) for symptom management 12, and the DASH diet includes moderate coffee and black tea consumption 13, green tea specifically should be avoided due to its unique catechin content and documented drug interactions 2.